1. Home
  2. ZURA vs FBYD Comparison

ZURA vs FBYD Comparison

Compare ZURA & FBYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zura Bio Limited

ZURA

Zura Bio Limited

HOLD

Current Price

$4.37

Market Cap

455.4M

Sector

Health Care

ML Signal

HOLD

FBYD

Falcon's Beyond Global Inc.

HOLD

Current Price

$17.05

Market Cap

811.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZURA
FBYD
Founded
2022
2021
Country
United States
United States
Employees
40
243
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
455.4M
811.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ZURA
FBYD
Price
$4.37
$17.05
Analyst Decision
Buy
Analyst Count
6
0
Target Price
$13.00
N/A
AVG Volume (30 Days)
627.8K
58.9K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$268.88
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$3.71
52 Week High
$7.25
$29.02

Technical Indicators

Market Signals
Indicator
ZURA
FBYD
Relative Strength Index (RSI) 38.08 61.25
Support Level $3.33 $10.17
Resistance Level $4.58 $18.77
Average True Range (ATR) 0.36 2.11
MACD -0.03 0.45
Stochastic Oscillator 26.33 59.27

Price Performance

Historical Comparison
ZURA
FBYD

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

About FBYD Falcon's Beyond Global Inc.

Falcons Beyond Global Inc is a visionary entertainment and technology enterprise. The group designs, develops, engineers, delivers, and commercializes immersive physical and digital experiences for brands, developers, and destination operators world-wide, as well as for its own portfolio of entertainment and technology concepts. The Company has five operating segments: Falcon's Creative Group, Destinations Operations, PDP, Falcon's Beyond Brands, and Falcon's Attractions. It earns the majority of the revenue from Falcon's Creative Group segment.

Share on Social Networks: